Research and Markets (http://www.researchandmarkets.com/research/9ba46c/non_small_cell_l)
has announced the addition of GlobalData 's new report "Non
- Small Cell Lung Cancer (NSCLC) - Drug Pipeline Analysis and Market
Forecasts to 2015" to their offering.
“Non
- Small Cell Lung Cancer (NSCLC) - Drug Pipeline Analysis and Market
Forecasts to 2015”
"Non-Small Cell Lung Cancer (NSCLC) - Drug Pipeline Analysis and Market
Forecasts to 2015" is an essential source of information and analysis on
the global NSCLC disease market. The report identifies the key trends
shaping and driving the global NSCLC disease market. The report also
provides insight on the prevalent competitive landscape and the emerging
players expected to bring significant shift in the market positioning of
the existing market leaders. Most importantly, the report provides
valuable insight on the pipeline products within the global NSCLC
disease sector.
This report is built using data and information sourced from proprietary
databases, primary and secondary research and in house analysis by a
team of industry experts.
NSCLC Market is Forecast to Show High Growth till 2015
The report estimates that the global NSCLC was valued at $2.8 billion in
2008 and is forecast to grow at a compound annual growth rate (CAGR) of
13.5% for the next seven years to reach $6.8 billion by 2015. This high
growth forecast is primarily attributed to the strong pipeline
landscape, population growth and release of new first in class drugs
with better safety and efficacy profiles. Low treatment seeking,
diagnosis and prescription rates and the availability of generics with
better efficacy and safety profiles, pose significant challenges for
prospective market entrants.
Unmet Need Continues to Remain Unaddressed
The report estimates that the prevailing market landscape remains weak
with few market players and none of their products seem to be satisfying
the unmet needs that exist in the NSCLC market. The current market
provides large scope for pipeline drugs that are strong in terms of
efficacy and safety. As patients become more aware of the latest
technological developments; increased efficacy, tolerability and safety
profiles will be the key factors that drive the acceptance and market
penetration of pipeline products. As the marketed products do not serve
the unmet need, the market continues to offer opportunities for stronger
pipeline candidates. However, considering the fact that a majority of
the pipeline products are first-in-class with proven superiority in
offering therapeutic performance, the existing market leaders will face
significant challenges in maintaining their market shares.
Major Companies Focus on NSCLC Drug Development Landscape
The authors expect that F. Hoffmann-La Roche Ltd, Pfizer Inc., Novartis
AG, Sanofi-aventis, Boehringer Ingelheim GmbH, and Abraxis BioScience,
Inc. will become the leading competitors in the global NSCLC market.
Currently, Roche and Eli Lilly are the leading players, with the
competitive landscape populated by six major products, none of which are
particularly dominant. However, companies like Roche, Pfizer, Novartis,
Sanofi-aventis, Boehringer Ingelheim, and Abraxis BioScience, with some
of the most technologically advanced products in their pipeline
portfolio, are expected to attract the most investor attention in the
coming years.
The existing market landscape remains weak with only six key products
approved and high unmet needs suggesting that the current competition is
ineffective. This could change in the near future following multiple
product launches by the leading and emerging manufacturers who are
concentrating on novel therapies like protein kinase inhibitors, DNA and
RNA synthesis inhibitors, C-Met or ALK Inhibitors, glutathione
S-transferase binders, growth and survival of MM cells inhibitors, and
HER2 dimerization inhibitors.
Scope of the Report